tetano
Editor, Senior Moderator
Eur J Gastroenterol Hepatol
. 2021 Dec 1;33(1S Suppl 1):e368-e374.
doi: 10.1097/MEG.0000000000002091.
Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis
Raymond Pranata[SUP] 1 [/SUP], Emir Yonas[SUP] 2 [/SUP], Ian Huang[SUP] 3 [/SUP], Michael Anthonius Lim[SUP] 1 [/SUP], Sally Aman Nasution[SUP] 4 [/SUP], Raden Ayu Tuty Kuswardhani[SUP] 5 [/SUP]
Affiliations
Abstract
Background/aims: In this meta-analysis, we aimed to evaluate the prognostic value of fibrosis-4 index (FIB-4) in COVID-19.
Methods: We performed a comprehensive literature search of PubMed, Embase, and Scopus databases on 26 November 2020. FIB-4 was calculated by [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. A value above cutoff point was considered high and a value below cutoff point was considered low. The main outcome was mortality, the association between high FIB-4 and mortality was reported in odds ratio (OR). Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), area under the curve (AUC) were generated.
Results: There were 963 patients from five studies included in this systematic review and meta-analysis. Meta-analysis showed that high FIB-4 was associated with increased mortality [OR 3.96 (2.16-7.27), P < 0.001; I2: 41.3%]. High FIB-4 was associated mortality with a sensitivity of 0.56 (0.40-0.70), specificity of 0.80 (0.72-0.86), PLR 2.8 (1.8-4.2), NLR 0.55 (0.39-0.78), DOR 5 (2-10), and AUC of 0.77 (0.73-0.81). Fagan's nomogram indicated that for a pre-test probability (mortality) of 30%, a high FIB-4 was associated with 54% post-test probability and a low FIB-4 was associated with 19%, respectively. The funnel-plot analysis was asymmetrical, trim-and-fill analysis by imputation of a study on the left side using linear estimator resulted in an OR of 3.48 (1.97-6.14). Egger's test showed no indication of small-study effects (P = 0.881).
Conclusion: High FIB-4 was associated with mortality in patients with COVID-19.
. 2021 Dec 1;33(1S Suppl 1):e368-e374.
doi: 10.1097/MEG.0000000000002091.
Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis
Raymond Pranata[SUP] 1 [/SUP], Emir Yonas[SUP] 2 [/SUP], Ian Huang[SUP] 3 [/SUP], Michael Anthonius Lim[SUP] 1 [/SUP], Sally Aman Nasution[SUP] 4 [/SUP], Raden Ayu Tuty Kuswardhani[SUP] 5 [/SUP]
Affiliations
- PMID: 35048648
- DOI: 10.1097/MEG.0000000000002091
Abstract
Background/aims: In this meta-analysis, we aimed to evaluate the prognostic value of fibrosis-4 index (FIB-4) in COVID-19.
Methods: We performed a comprehensive literature search of PubMed, Embase, and Scopus databases on 26 November 2020. FIB-4 was calculated by [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. A value above cutoff point was considered high and a value below cutoff point was considered low. The main outcome was mortality, the association between high FIB-4 and mortality was reported in odds ratio (OR). Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), area under the curve (AUC) were generated.
Results: There were 963 patients from five studies included in this systematic review and meta-analysis. Meta-analysis showed that high FIB-4 was associated with increased mortality [OR 3.96 (2.16-7.27), P < 0.001; I2: 41.3%]. High FIB-4 was associated mortality with a sensitivity of 0.56 (0.40-0.70), specificity of 0.80 (0.72-0.86), PLR 2.8 (1.8-4.2), NLR 0.55 (0.39-0.78), DOR 5 (2-10), and AUC of 0.77 (0.73-0.81). Fagan's nomogram indicated that for a pre-test probability (mortality) of 30%, a high FIB-4 was associated with 54% post-test probability and a low FIB-4 was associated with 19%, respectively. The funnel-plot analysis was asymmetrical, trim-and-fill analysis by imputation of a study on the left side using linear estimator resulted in an OR of 3.48 (1.97-6.14). Egger's test showed no indication of small-study effects (P = 0.881).
Conclusion: High FIB-4 was associated with mortality in patients with COVID-19.